LATS1 and neoplasm: For example, Novartis recently described a series of biaryl-derivatives as direct YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitors [50], and the clinical candidate derived from this series, IAG933 (ClinicalTrials.gov ID NCT04857372) elicited complete tumor regression in a xenograft model of LATS1/2 deficient mesothelioma (MSTO-211H) [51].